Validation of an Assay Procedure for Ormustine in a Liposomal Dosage Form


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

A spectrophotometric assay for ormustine active ingredient for a liposomal dosage form with antitumor activity was selected and validated for specificity, linearity, accuracy, precision, and intermediate (intralaboratory) precision in order to ensure accurate and precise results. The obtained statistical characteristics were shown to satisfy acceptance criteria for the validation parameters given in domestic regulatory documentation. Ormustine was determined at 396 ± 2 nm because excipients in the dosage form did not absorb in this spectral region. The correlation coefficient for the linearity was >0.997. The relative error of the mean result was <1% for the accuracy. The confidence interval included 100%. The coefficient of variation for the precision and intermediate precision determinations was <1%. The studied method could be used in the range 80 – 120% of the nominal ormustine content in the liposomal dosage form.

Об авторах

N. Bunyatyan

M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Автор, ответственный за переписку.
Email: ndbun@mail.ru
Россия, 8/2 Trubetskaya St., Moscow, 119991; 8/2 Petrovskii Blvd., Moscow, 127051

N. Oborotova

M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; N. N. Blokhin National Medical Research Center of Oncology (N. N. Blokhin NMRCO), Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, 8/2 Trubetskaya St., Moscow, 119991; 24 Kashirskoe Shosse, Moscow, 115478

L. Nikolaeva

M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; N. N. Blokhin National Medical Research Center of Oncology (N. N. Blokhin NMRCO), Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, 8/2 Trubetskaya St., Moscow, 119991; 24 Kashirskoe Shosse, Moscow, 115478

E. Ignat’eva

N. N. Blokhin National Medical Research Center of Oncology (N. N. Blokhin NMRCO), Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, 24 Kashirskoe Shosse, Moscow, 115478

I. Yartseva

N. N. Blokhin National Medical Research Center of Oncology (N. N. Blokhin NMRCO), Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, 24 Kashirskoe Shosse, Moscow, 115478

A. Lantsova

N. N. Blokhin National Medical Research Center of Oncology (N. N. Blokhin NMRCO), Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, 24 Kashirskoe Shosse, Moscow, 115478

A. Prokof’ev

M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, 8/2 Trubetskaya St., Moscow, 119991; 8/2 Petrovskii Blvd., Moscow, 127051


© Springer Science+Business Media, LLC, part of Springer Nature, 2018

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах